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Available online 16 October 2013Abstract Human embryonic stem cells (hESCs) were used as a model system of human pancreas development to study
characteristics of the polyhormonal cells that arise during fetal pancreas development. HESCs were differentiated into fetal-like
pancreatic cells in vitro using a 33-day, 7-stage protocol. Cultures were ~90–95% PDX1-positive by day (d) 11 and 70–75%
NKX6.1-positive by d17. Polyhormonal cells were scattered at d17, but developed into islet-like clusters that expressed key
transcription factors by d33. Human C-peptide and glucagon secretion were first detected at d17 and increased thereafter in parallel
with INS and GCG transcript levels. HESC-derived cells were responsive to KCl and arginine, but not glucose in perifusion studies.
Compared to adult human islets, hESC-derived cells expressed ~10-fold higher levels of glucose transporter 1 (GLUT1) mRNA, but
similar levels of glucokinase (GCK). In situ hybridization confirmed the presence ofGLUT1 transcript within endocrine cells. However,
GLUT1 protein was excluded from this population and was instead observed predominantly in non-endocrine cells, whereas GCK was
co-expressed in insulin-positive cells. In rubidium efflux assays, hESC-derived cells displayed mild potassium channel activity, but no
responsiveness to glucose, metabolic inhibitors or glibenclamide. Western blotting experiments revealed that the higher molecular
weight SUR1 band was absent in hESC-derived cells, suggesting a lack of functional KATP channels at the cell surface. In addition, KATP
channel subunit transcript levels were not at a 1:1 ratio, as would be expected (SUR1 levels were ~5-fold lower than KIR6.2). Various
ratios of SUR1:KIR6.2 plasmids were transfected into COSM6 cells and rubidium efflux was found to be particularly sensitive to a
reduction in SUR1. These data suggest that an impaired ratio of SUR1:KIR6.2 may contribute to the observed KATP channel defects in
hESC-derived islet endocrine cells, and along with lack of GLUT1, may explain the absence of glucose-stimulated insulin secretion.
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Diabetes is a chronic disease characterized by elevated
circulating glucose levels and debilitating long-term health
complications. Patients with either type 1 or 2 diabetes suffer
from insulin insufficiency and loss of pancreatic β-cells,
albeit via different mechanisms (Mathis et al., 2001; Donath
and Halban, 2004). Strategies to restore regulated insulin
production in diabetic patients include regeneration of
endogenous pancreatic β-cells via neogenesis from a resident
progenitor cell population, proliferation of pre-existing β-cells
or transdifferentiation from a closely related non β-cell
type (Tuduri et al., 2012; Bonner-Weir and Weir, 2005).
Alternatively, an exogenous source of insulin-secreting β-cells,
such as cadaveric human islets, porcine islets or human
embryonic stem cell (hESC)-derived cells could be transplanted
into diabetic patients to restore insulin secretion (Tuduri et al.,
2012; Guo and Hebrok, 2009; Bruin and Kieffer, 2012). Despite
exciting progress in generating glucose-responsive insulin
secreting cells following transplantation of hESC-derived
pancreatic progenitor cells (Kroon et al., 2008; Rezania et al.,
2012; Bruin et al., 2013; Rezania et al., 2013), this process has
not yet been replicated in vitro. Instead, most studies report
the formation of polyhormonal insulin-expressing cells from
hESCs that resemble the transient endocrine cells observed in a
mid-gestation human fetal pancreas (Kroon et al., 2008;
Rezania et al., 2012; Bruin et al., 2013; Nostro et al., 2011;
D'Amour et al., 2006; Rezania et al., 2011; J. Jiang et al., 2007;
Chen et al., 2009; Xu et al., 2011). The role and fate of
polyhormonal pancreas cells during human fetal development
are poorly understood, although immunohistochemical charac-
terization indicated that these cells possess an α-cell
transcription factor profile (Riedel, 2011). Moreover, several
reports describe the formation of α-cells in vivo following
transplantation of hESC-derived polyhormonal cells (Rezania
et al., 2011; Kelly et al., 2011; Basford et al., 2012; Rezania et
al., 2013). Further characterization of insulin/glucagon co-
expressing cells may provide insight into the possible function
and fate of these cells during human pancreas development.
Here, we characterized a new differentiation protocol to
model human pancreas development in vitro. Since only roughly
1% of the human pancreas is composed of endocrine cells, our
goal was not to maximize the endocrine compartment, but
rather to assess how closely the mixed population of hESC-
derived cells resembled the developing whole human pancreas.
Secondly, we utilized this model system to study characteristics
of hESC-derived polyhormonal cells. Although insight has been
gained into the RNA profile of hESC-derived polyhormonal cells
from previous studies (D'Amour et al., 2006; Kelly et al., 2011;
Basford et al., 2012), there is still much to be learned about the
protein profile and function of these cells. For instance, we
still do not understand which features of mature β-cells are
lacking in hESC-derived insulin/glucagon co-positive cells and
preventing them from secreting insulin in response to a
glucose stimulus. Previous studies characterized polyhor-
monal cells following cell sorting, which has the advantage
of a pure population for RNA analysis (Kelly et al., 2011;
Basford et al., 2012). To complement studies in isolated cells,
we examined the functional andmorphological characteristics
of intact polyhormonal cells within their culture environment,
thus maintaining the normal cell–cell interactions and
preserving their cellular niche.Materials and methods
In vitro differentiation of hESCs
All differentiation experiments for the protocol development
(Fig. 1) were performed with H1 hESCs, obtained from WiCell
Research Institute, Inc. (Madison, WI). The optimized 33-day,
7-stage differentiation protocol (Fig. 2A, Supplementary
Tables 1–2) was then applied to the CA1S hESC line, derived
from the parental CA1 line (Amps et al., 2011). These cells
maintain pluripotency markers and the ability to generate all
germ layers when transplanted into nude mice (Caron et al.,
2013). CA1S cells are more conducive to single cell seeding
than the parental CA1 cells and as such, are an excellent line
for generating homogenous and uniform cultures (Caron et al.,
2013; Schulze et al., 2010). All experiments at UBC with H1
and CA1S cells were approved by the Canadian Stem Cell
Oversight Committee and UBC Clinical Research Ethics Board.
H1 and CA1S cells were both cultured in mTesR1 media
(Stem Cell Technologies, Vancouver BC, Canada) on 1:30
Matrigel coated surfaces (Stem Cell Technologies). Once
cells reached ~90–95% confluence, hESCs were directed
through 7 stages of pancreatic development over a period of
33 days according to the details provided in Supplementary
Tables 1–2 and as summarized in Fig. 2A. Differentiation
culture media was changed daily during stages 1–6 and every
other day during stage 7.
Flow cytometry
HESC-derived cells were released into single-cell suspension
by incubation in Accutase (Stem Cell Technologies) at 37 °C
for 10 min. For surface marker staining, cells were washed
twice in staining/wash buffer with 5% FBS (BD Biosciences).
Cells (1 × 105) were re-suspended in 150 μl staining buffer and
then incubated with conjugated primary antibody anti-CXCR4
(R&D Systems #FAB170P) for 1 h at room temperature (RT).
Cells were washed twice with staining/wash buffer prior to
analysis on the BD FACS LSR II.
For intracellular antibody staining, cells were fixed in
250 μl of Cytofix/Cytoperm Buffer (BD Biosciences) for 20 min
at 4 °C and then washed with Perm/Wash Buffer Solution (BD
Biosciences). Cells were re-suspended in 150 μl Perm/Wash
Buffer and then incubated for 1 h at RT with primary
antibodies followed by 1 h in secondary antibodies and two
washes prior to analysis on the BD FACS LSR II. Primary
antibody details are as follows: rabbit anti-insulin (1:50; Cell
Signaling #C27C9; Danvers, MA), mouse anti-NKX6.1 (1:50;
DSHB #F55A12; University of Iowa); mouse anti-PDX1 (1:100;
BD #562161). Secondary antibodies were goat anti-mouse
Alexa 647 (1:500; Invitrogen) or goat anti-rabbit PE (1:200;
Invitrogen).
Immunofluorescent staining
In situ staining
hESC-derived cells were washed with PBS and immediately
fixed with 4% PFA on the plate at 4 °C overnight. Cells were
washed with PBS, permeabilized with 0.2% TritonX-100 for
20 min and incubated with protein blocking solution (Dako;
Glostrup, Denmark) for 1 h at RT. Primary antibodies were
Figure 1 Optimization of in vitro differentiation protocol in H1 cells. A) The effect of various glucose concentrations, ranging from 5
to 30 mM, during stages 3–6 (S3–6) on gene expression was examined. Red bar indicates the glucose concentration selected for the final
protocol. B) Expression of pancreas-related genes was examined at the end of stages 3 or 4 following addition of activin a (AA) and/or
fibroblast growth factor 7 (FGF7, F7) during stage 3. C) A small molecule CYP26A inhibitor was added at doses ranging from 10 to 500 nM
during stage 4. 100 nM (red bar) was chosen as the optimal concentration for the final protocol. All data are presented as mean ± s.e.m.
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were washed 5× with PBS and incubated in secondary
antibodies for 90 min at RT: goat anti-guinea pig AF488
(1:500; Life Technologies) or donkey anti-rabbit AF555 (1:500;
Life Technologies). Cells were washed 5× with PBS and
counterstained with Hoechst 33342 (10 μg/ml; Invitrogen) for
30 min at RT. PBS was added to the wells and images were
captured using the ImageXpressMicro™ Imaging System and
analyzed using MetaXpress Software (Molecular Devices
Corporation, Sunnyvale, CA, USA).Paraffin-embedded sections
hESC-derived cells were incubated in Accutase for ~2 min and
cell sheets were gently lifted from the well with a cell scraper.
The intact cell sheet was fixed overnight in 4% PFA at 4 °C,
embedded in 1% agarose and then stored in 70% ethanol prior to
paraffin-embedding and sectioning (5 μm thickness; Wax-it
Histology Services, Vancouver, BC Canada). Paraffin-embedded
human pancreas sections were used as a positive control for
antibody conditions (Irving K. Barber Human Islet Isolation
Laboratory; Vancouver, BC). Immunofluorescent staining was
performed as previously described (Rezania et al., 2012).Primary antibodies are detailed in Supplementary Table 3.
Images were captured as described above.In situ hybridization
Paraffin embedded hESC-derived cells were prepared and
sectioned as above (see immunofluorescent staining). In situ
hybridization was performed with the IsHyb In Situ Hy-
bridization kit (Biochain, San Francisco, California). Briefly,
slides were de-paraffinized with three consecutive xylene
washes, rehydrated with graded ethanol washes. Sections
were fixed with 4% PFA for 20 min, and treated with 10 μg/ml
Proteinase K (Sigma Aldrich) at 37 °C for 15 min. Sections
were incubated for 4 h at 50 °C in pre-hybridization solution
(Biochain). Probe for human SLC2A1 mRNA (NM_006516)
(GLUT1) was designed and custom synthesized with a 5′DIG
label at IDT Oligo (Vancouver, Canada). Slides were incubated
with the 5′DIG labeled GLUT-1 probe (AAGCACATGCCCAC
AATGAAATTTGAGGTCC) in hybridization solution (Biochain)
for 14 h at 50 °C. Control sections were incubated in hy-
bridization solution alone. Slides were then washed in different
concentration of saline-sodium citrate (SSC) buffers (2×, 1.5×,
Figure 2 Summary of in vitro differentiation protocol checkpoints in CA1S cells. A) Schematic summary of the 7-stage, 33-day
differentiation protocol. B) Expression of key checkpoint proteins throughout the differentiation, illustrating the typical efficiency of
pancreatic cell development at various stages. C) Images of in situ immunofluorescent staining for key checkpoint markers in
differentiating 12-well cultures at day 11, 19 and 26. Hoescht (blue) marks nuclei and is shown only in the top image at day 11 and the
top left images at days 19 and 26. At day 11 and 19 scale bars = 50 μm. At day 26 rare cells co-expressing both NKX6.1 and insulin
(white arrow) are shown; scale bars = 100 μm.
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solution (Biochain) for 1 h. Slides were incubated overnight
with alkaline-phosphate conjugated anti-digoxinogen antibody
(diluted 1:500 in PBS; Biochain) at 4 °C. The following day,
slides were washed with PBS and alkaline phosphatase buffer
(Biochain) and incubated with nitro-blue tetrazolium chloride
(NBT) and 5-bromo-4-chloro-3′-indolyphosphate p-toluidine
salt (BCIP) solution (6.6 μl NBT and 3.3 μl BCIP were diluted in
1 ml alkaline phosphatase buffer; Biochain) for 48 h at 4 °C.
Sections were then immunostained for insulin, glucagon and
DAPI as indicated above using the following antibodies: guinea
pig anti-insulin (Sigma Aldrich), mouse anti-glucagon (Sigma
Aldrich), Alexa Fluor® 594 goat anti-guinea pig IgG (Life
Technologies, Carlsbad, California) and Alexa Fluor® 488
donkey anti-mouse IgG (Life Technologies). Fluorescent and
bright field images were obtained with Openlab software
(PerkinElmer).Quantitative RT-PCR
qPCR
At each stage of differentiation hESC-derived cells were
incubated in Accutase for 10 min, washed with PBS and
stored in Buffer RLT (Qiagen, Hilden, Germany) at −80 °C.
RNA extraction was performed using the RNeasy kit (Qiagen)
with on-column DNase digestion according to manufacturer's
instructions. cDNA synthesis was performed using the
iSCRIPT kit (Biorad, Mississauga, ON Canada). Quantitative
PCR was performed using the SsoFast EvaGreen Supermix
with Low ROX master mix (Bio-Rad) and run on a StepOne
Plus Real Time PCR machine (Applied Biosystems). HPRT was
used as a reference gene. Data were analyzed using the ΔΔCT
method. Primer sequences are listed in Supplementary Table
4. Gene expression in hESC-derived cells was normalized
either to undifferentiated CA1S cells (Supplementary Fig.
1A-F), adult human islets (Supplementary Figs. 1G, 1H and
Fig. 7D) or adult human pancreas (Supplementary Fig. 1H).
Human islets were kindly provided by the Irving K. Barber
Human Islet Isolation Laboratory (Vancouver, BC). Human
pancreas total RNA was purchased from Life Technologies
(Cat# AM7954).SA biosciences array
RNA isolation, cDNA synthesis and qPCR were performed in
day (d) 33 cells as described above, but using a custom
designed PCR array (primers provided in Supplementary
Table 5; SA Biosciences). Data analysis was performed using
the online RT2 Profiler PCR Array Data Analysis Tool. Gene
expression is presented as the fold change relative to adult
human islets (n = 3).Applied biosytems array
Gene expression profiles of H1 cells were assessed by custom
Taqman qPCR Arrays (Applied Biosystems, Foster City, CA),
as described previously (Rezania et al., 2012). Data were
analyzed using Sequence Detection Software (Applied
Biosystems) and normalized to a housekeeping gene
(GAPDH) using the ΔΔCT method. Primers are provided in
Supplementary Table 6.Total cell extraction and western blotting
CA1S cells from different stages of differentiation (d7-d33) and
HL-1 cells were lysed in RIPA buffer (50 mM Tris pH 8, 400 mM
NaCl, 0.5% Triton NP-40, 1% DOC, 0.1% SDS, 1 μg/ml pepstatin,
1 μg/ml bestatin, 2 μg/ml leupeptin, 2 mM PMSF, 10 mM
β-Glycerophosphate, 1 mM NaF, 1 mM DTT), homogenized
with a needle and syringe, and rotated for 20 min at 4 °C.
Lysate was centrifuged for 20 min at 4 °C at 14,000 rpm. Total
proteins were loaded on a 7.5% SDS gel and transferred to
nitrocellulose membrane and blotted with anti-SUR1 antibody
(NeuroMAb, clone N289/16), goat anti-mouse secondary
antibody (ABM, Vancouver, BC). Signal was detected with ECL
methods (Femto ECL reagent, Pierce).
Hormone secretion
Basal hormone secretion
Media was collected from cells after a 24 h incubation period
on the indicated days of differentiation (Figs. 5A,B),
centrifuged briefly and stored at −30 °C. Samples were
assayed for C-peptide and glucagon via radioimmunoassay
(Millipore, Billerica, MA).
Perifusion protocol 1
D33 cells were loaded into temperature-/CO2-controlled
chambers of an Endotronics Acu-syst S Perifusion apparatus.
Cells from 4 wells of a 6-well plate were pooled for each
individual column. HEPES-buffered Krebs Ringers Bicarbonate
Buffer (KRBB) containing 0.5% BSA and 3 mM glucose was
pumped through the chambers at ~350 μl/min following a
35 min preincubation under basal conditions. Fractions were
then collected throughout the 170 min perifusion protocol, as
indicated in Figs. 5C,D. All sampleswere assayed for C-peptide
and glucagon via radioimmunoassay (Millipore).
Perifusion protocol 2
To determine if the cells were desensitized to glucose after
long-term culture in 25 mM glucose, cells were cultured
throughout from d20 to 33 in stage 7 media (Supplementary
Table 1) containing low (8 mM) or high (25 mM) glucose. D33
cells (low or high glucose) were transferred to stage 7 culture
media containing 3 mM glucose for 2 h before transfer to
perifusion columns (4 wells per column). Once contained
within the perifusion apparatus, cells were incubated under
basal conditions for 1 h and then fractions were collected
throughout the 250 min perifusion protocol, as indicated in
Fig. 6B. All samples were assayed for insulin via radioim-
munoassay (Millipore).
Non-radioactive rubidium efflux assay
β-cell lines and hESC-derived cells
A non-radioactive rubidium (Rb+) efflux assay was used as a
measure of KATP channel activity (Li et al., 2013). Cells were
loaded for 1 h with Rb+ loading media (5.4 mM RbCl, 150 mM
NaCl, 2 mM CaCl2, 0.8 mM NaH2PO4, 1 mM MgCl2, 5 mM
glucose, 25 mM HEPES, pH 7.4), washed 2X with PBS, and
incubated in assay buffer (118 mMNaCl, 2.5 mMCaCl2, 1.2 mM
KH2PO4, 4.7 mM KCl, 25 mM NaHCO3, 1.2 mM MgSO4, 10 mM
HEPES, pH 7.4) supplemented with glucose, glibenclamide, or
199Modeling human fetal pancreasmetabolic inhibitors (2.5 μg/ml oligomycin, 1 mM 2-deoxy-
D-glucose) as indicated. Aliquots of the assay buffer were
removed atmultiple time points (5, 10, 20, 40 min) and the Rb+
concentration in the supernatant was determined by flame
atomic absorption spectroscopy using an Aurora Biomed
ICR8000 instrument. Rubidium efflux was represented as a
fraction of total loaded Rb+ (determined as the sumof extruded
Rb+ and Rb+ left in lysed cells at the end of the assay).
Transfected COSM6 cells
COSM6 cells were maintained in culture in a 5% CO2 incubator
at 37 °C in DMEM supplemented with 10% FBS and penicillin/
streptomycin. COSM6 cells in 24 well plates were transiently
transfected with mouse SUR1 and hamster Kir6.2 cDNAs
(expressed in pcDNA3.1-) in various ratios (400 ng total DNA
per well) using jetPRIME (Polyplus), and Rb + efflux assays
were performed after 2 days. As the total amounts of Kir6.2
and SUR1 plasmids were reduced, additional GFP vector was
added to match the total transfected DNA in each well. For
efflux assays, cells were loaded overnight by adding 3 mM
RbCl to the cell culture medium. Just before the experiment,
cells were washed twice quickly with PBS. Cells were then
incubated in assay buffer supplemented with metabolic
inhibitors (as described above). Aliquots of the assay buffer
were removed at multiple time points (5, 10, 20, 40 min) and
the Rb+ concentration was determined as described above.
For clarity of figure presentation, data was normalized
to efflux from WT Kir6.2 transfected cells (normalized
Rb + efflux = (EffluxMutant − EffluxUntransfected)/(EffluxWT Kir6.2 −
EffluxUntransfected). However, raw efflux data was used for
statistical tests. For simplicity, only data from the 40 min
time point has been presented.
Trypsin activity assay
At day 33, cell pellets from hESC-derived cells were harvested
and stored at −80 °C. Trypsin activity was measured using a
commercial colorimetric Trypsin Activity Assay Kit according
to manufacturer's instructions (Abcam Inc., Toronto, ON
Canada).
Statistical analysis
Graphpad Software (La Jolla, CA) was used for all statistical
analysis. Specific statistical tests are described in figure
legends. Statistical significance was considered p b 0.05. All
data are presented as mean ± s.e.m.
Results
Modification of the differentiation protocol in
H1 cells
Our previous protocol (Rezania et al., 2012) was revised to
incorporate a number of changes designed to improve the
overall quality of cultures and enhance efficiency of definitive
endoderm, pancreatic endoderm and endocrine progenitor
formation in H1 cells. In our previous protocol as well as most
previously published studies (Kroon et al., 2008; Nostro et al.,
2011; D'Amour et al., 2006; Xu et al., 2011; W. Jiang et al.,2007; Cai et al., 2010; Mfopou et al., 2010) various media
formulations were used at different stages of differentiation.
To simplify the protocol, we empirically tested many
commercially available media formulations (data not shown)
and identified that the MCDB 131 media formulation could be
used throughout the entire protocol. At stage 1, we replaced
activin A (AA)/WNT3A with GDF8/GSK3β inhibitor to further
enhance efficiency of definitive endoderm production, as
measured by expression of CXCR4 (AA/WNT3A vs GDF8/GSK3β:
84.8 ± 2.55 vs 96.8 ± 0.95% CXCR4, p b 0.05). Consistent with
previous results (Bone et al., 2011), addition of a GSK3β
inhibitor instead of WNT3A improved efficiency of definitive
endoderm generation. Furthermore, GDF8, a TGFβ family
member, proved as effective as activin A for inducing
definitive endoderm and is a more economical option. At
stage 3 onwards we tested the effect of various glucose
concentrations and demonstrated that high glucose (15 –
30 mM) enhanced gene expression of pancreatic endoderm
and endocrine markers compared to low glucose conditions
(Fig. 1A). For the final differentiation protocol, we opted to
increase the glucose concentration from 7.5 mM during stages
1–2 to 25 mM during stages 3–7. We also replaced Noggin with
a small molecule inhibitor of BMP receptor and added AA and
FGF7 to enhance expression of foregut endoderm markers
while suppressing endocrine precursor markers at stage 3
(Fig. 1B). The rationale for suppressing endocrine precursor
markers at stage 3 was to potentially reduce number of
polyhormonal cells at later stages of differentiation (Johansson
et al., 2007). Previous reports (Kinkel et al., 2009) indicated
that inhibition of CYP26A enzyme could expand the pancreatic
domain during regionalization of endoderm fields. Indeed,
addition of a small molecule inhibitor of CYP26A at stage 4
resulted in enhanced expression of pancreatic endoderm and
endocrine precursor markers; 100 nM was selected as the
optimal concentration of the CYP26A inhibitor for the final
protocol (Fig. 1C). Vitamin A (a precursor of retinoic acid) was
included during the final stage of differentiation because low
doses of retinoic acid were previously shown to enhance insulin
expression in e10.5 pancreas explants from mice (Ostrom et
al., 2008). We consistently observed a slight reduction in the
number of polyhormonal cells with the addition of retinoic acid
during stage 7 (A Rezania, unpublished observations). Lastly,
we replaced FBS at stages 1–2 and B27 at stages 3–7 with BSA
and BSA plus ITS-X, respectively.Assessment of pancreas markers throughout
differentiation in CA1S cells
The revised 33-day differentiation protocol (Fig. 2A) was next
characterized in CA1S cells. We first sought to determine
checkpoints for key markers of developing pancreas lineage
cells throughout differentiation. Representative flow cytometry
plots are shown in Fig. 2B. At the end of stage 1 (d5), cultures
typically expressed ~95–97% CXCR4, a marker of definitive
endoderm, but cultures with N90% CXCR4-positive cells were
considered acceptable to proceedwith differentiation (Fig. 2B).
At the end of stage 3 (d11), cultures of pancreatic endoderm
cells were typically between 90 and 95% PDX1-positive,
although cultures containing N90% PDX1 were accepted.
At the end of stage 5 (d17–18), the pancreatic endocrine
progenitor population maintained robust PDX1 expression
200 J.E. Bruin et al.(illustrated in Fig. 2C) and 70–75% of cells expressed
NKX6.1 (cultures containing N70% NKX6.1-positive cells were
accepted). During the final stage of differentiation (d20–33),
insulin was typically expressed in 6–10% of cells (Fig. 2B).
In situ immunofluorescent staining was also performed at
our key checkpoints (Fig. 2C). Cultures displayed highly uniform
nuclear PDX1 expression at the end of stage 3, which was
maintained throughout the differentiation. During stage 6
PDX1-positive cells co-expressed variable levels of NKX6.1,
creating a mosaic pattern of pancreatic endocrine progenitors.
NKX6.1 expression was maintained throughout stage 7, but only
rare NKX6.1/PDX1-positive cells co-expressed insulin. Insulin-
positive/NKX6.1-negative cells were dispersed throughout the
cultures at d26.
Wenext assessed gene expression of key pancreasmarkers in
whole cultures throughout differentiation. Pancreas-specific
transcription factors were initially detected at the end of stage
3 and maintained until the end of differentiation; PDX1 was
detected first, beginning at d11, followed next by NKX6.1 and
ARX beginning at d14 (Supplementary Fig. 1A). Gene expression
of INS and GCG was detected at d17 and increased throughout
stages 5–7 (Supplementary Fig. 1A). Amylase (AMY2A) was
consistently expressed at relatively low levels throughout the
differentiation (Supplementary Fig. 1A). To put these transcript
levels in perspective, gene expression in hESC-derived d33 cells
was compared to adult human islets. Notably, a marked
upregulation (~60-fold) of the pancreatic endocrine progenitor
marker NGN3 was observed in the hESC-derived cultures
relative to adult islets (Supplementary Fig. 1B). PDX1, SOX9,
MAFB and ARX were also substantially upregulated. Most other
pancreas transcription factors were expressed at similar levels
to adult islets, with the exception of MAFA and PTF1A, which
were markedly downregulated (Supplementary Fig. 1B).
Pancreatic hormones, INS, IAPP and PP were much lower than
in islets, whereas GCG and SST were similar, and GHRL levels
were ~10-fold higher (Supplementary Fig. 1B). Interestingly,
β-cell markers INS, NKX6.1 and PDX1 were expressed at levels
more similar to whole human pancreas than isolated human
islets (Supplementary Fig. 1C) and INS transcript levels were
equivalent to that of a 10 week gestational age human fetal
pancreas (J Bruin and S Erener, unpublished observations).
In contrast, α-cell markers GCG and ARX were more similar
to isolated human islet levels than whole pancreas
(Supplementary Fig. 1C).
Immunofluorescent staining of paraffin-embedded mono-
layer cultures confirmed the appearance of pancreatic
endocrine cells in differentiating cells beginning at d17 and
increasing in frequency thereafter (Fig. 3A). Distinct islet-
like endocrine clusters were observed at d33 and were
generally polyhormonal, with most cells expressing either
two or three of insulin, glucagon and/or somatostatin
(Fig. 3B). Ghrelin-positive cells were present within the
bud structures, but surprisingly did not co-localize with
chromogranin A (Supplementary Fig. 2A). Rare cells expressing
pancreatic polypeptide were also detected in the cultures
(Supplementary Fig. 2B). NKX6.1 and NKX2.2 were generally
localized within the endocrine buds, but in distinct com-
partments; NKX6.1 was expressed in non-endocrine cells
(Fig. 3C), whereas NKX2.2 was expressed in insulin/glucagon
co-positive cells (Fig. 3D).
A pro-insulin antibody specific for the intact B/C junction
of pro-insulin revealed pro-insulin immunoreactivity in themajority of insulin expressing cells at d33 (Fig. 3E), suggesting
that insulin produced by hESCs was incompletely processed.
To further investigate, we next examined expression of
pro-hormone processing enzymes, which are required for
production of functional pancreatic hormones. Gene array
results revealed significantly lower levels of both prohormone
convertase (PC) 1/3 and 2 compared to human islets
(Supplementary Fig. 3). PC2 protein was detected in nearly
all insulin-positive cells at d33 (Fig. 3F), whereas PC1/3
expression was heterogeneous (Fig. 3G). Similarly, the
majority of insulin/glucagon double-positive cells expressed
PC2 but not PC1/3. A substantial number of insulin-positive/
PC1/3-negative cells and insulin-negative/glucagon-negative/
PC1/3-positive cells were observed within the endocrine
clusters (Fig. 3G), suggesting that lack of PC1/3 could be the
underlying cause of incomplete insulin processing in hESC-
derived cells.
Lastly, non-endocrine pancreas markers were examined in
the d33 cultures (Fig. 4). Immunoreactivity for trypsin, an
enzyme found in developing and mature pancreatic acinar
cells, was expressed throughout the cultures, including within
the endocrine cells (Fig. 4A). Pancreatic secretory trypsin
inhibitor (PSTI) was also co-expressed in the endocrine
clusters (Fig. 4B). Yet, the surrounding trypsin-positive cells
did not express other markers of mature exocrine tissue, such
as carboxypeptidase A1 (CPA1; Figs. 4C-D) suggesting that
these acinar cells were immature. Indeed a trypsin activity
assay revealed that media secreted from d33 cultures had no
detectable trypsin activity (data not shown). Interestingly,
rare CPA1-positive cells were found to be co-localized with
synaptophysin (Fig. 4C, white arrows). CK19, a ductal marker,
was widely expressed throughout the cultures and also within
the bud structures, but in a separate compartment from the
endocrine cells (Figs. 4D–F). This pattern of CK19 expression
(adjacent to endocrine cells within the bud structures)
resembles that of NKX6.1 (Fig. 3C), indicating that NKX6.1
was co-expressed within this subset of ductal cells. Indeed,
immunostaining for transcription factors PDX1 and NKX6.1
revealed that CK19 was co-localized with the majority of
NKX6.1 expressing cells (Fig. 4E) and alsowith PDX1 expressing
cells (Fig. 4F) albeit more heterogeneously.Regulation of hormone secretion by hESC-derived
endocrine cells
To assess the function of hESC-derived pancreatic endocrine
cells, we first measured basal hormone secretion at all stages of
differentiation. Corresponding to the timeline of detectable
RNA and protein expression (Supplementary Fig. 1A and Fig. 3A,
respectively), human C-peptide and glucagon were first
detected in the culture media at d17 (Figs. 5A and B,
respectively). Hormone secretion increased steadily throughout
stages 6 and 7, and peak hormone levels were detected at d26
(Figs. 5A–B). Perifusion experiments at d33 revealed that
C-peptide and glucagon secretion were both regulated by
30 mM KCl and 15 mM arginine, but not 15 mM glucose (Figs. 5C
and D).
Since cells had been cultured in media containing 25 mM
glucose throughout stages 3–7, we speculated that the
hESC-derived endocrine cells might be desensitized to high
glucose and consequently, the switch from 3 to 15 mM
Figure 3 Characterization of pancreatic hormones and prohormone processing enzymes in hESC-derived cultures.
A) Scattered endocrine cells were first detected at day 17 and increased in number by day 20. At day 33, endocrine cells were
clustered in islet-like buds throughout the monolayer cultures. At all stages, most insulin-positive cells co-expressed glucagon.
Magnified insets are shown in the right panels. Scale bars = 100 μm. B–D) Characterization of endocrine buds at day 33; low
magnification images are provided in the left panels and insets of endocrine buds are shown on the right with individual channels;
scale bars = 50 μm. E) At day 33, proinsulin-positive cells are shown. Scale bars = 50 μm. F–G) Immunofluorescent staining revealed
that prohormone convertase 2 (PC2) was expressed in all insulin-positive cells (panel F), whereas PC1/3 expression was
heterogeneous and many insulin-positive/PC1/3-negative cells were observed (panel G). Scale bars = 50 μm.
201Modeling human fetal pancreasglucose during perifusion may simply have been inadequate to
stimulate insulin secretion. Therefore, stage 7 cells were
cultured in either high (25 mM) or low (8 mM) glucose media.
At d26, two independent experiments demonstrated that
basal human C-peptide secretion was significantly higher in
cells exposed to 8 mM glucose compared to 25 mM glucose
(Fig. 5E). Perifusion at d33 showed a trend towards elevated
insulin secretion in response to KCl and arginine by cells
cultured in low glucose stage 7 media, but no change in
response to glucose (Fig. 5F), suggesting that desensitizationalone does not explain the lack of glucose-stimulated insulin
secretion.Characteristics of hESC-derived
insulin-secreting cells
Glucose transport and sensing components
To further characterize the hESC-derived insulin/glucagon
co-positive cells, we next assessed various components of the
Figure 4 Characterization of exocrine and ductal markers in hESC-derived cells at day 33. A) Trypsin was weakly expressed
throughout cultures and also co-expressed within endocrine cells (marked by synaptophysin). B) Pancreatic secretory trypsin inhibitor
(PSTI) was also expressed in hESC-derived insulin-positive cells. C–D) Rare carboxypeptidase A1 (CPA1)-positive cells were detected
at day 33, but these were generally co-localized in endocrine cells (panel C insets; white arrows). C–F) Ductal marker, CK19, was
widely expressed throughout the culture and also located within the bud structures. E–F) Costaining of CK19 with transcription
factors NKX6.1 (panel E) and PDX1 (panel F). All scale bars = 100 μm.
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Figure 5 Hormone secretion from hESC-derived cells throughout differentiation. A–B) Basal secretion of human C-peptide
(A) and glucagon (B) following a 24 h incubation period in culture media at each stage of differentiation. C-peptide and glucagon
levels are presented as the average of 6 – 8 independent differentiation trials. C–D) Hormone secretion in response to various
secretagogues was assessed at day 33 by perifusion (cells were harvested as intact monolayers to preserve cell morphology). Panel C,
mean ± s.e.m C-peptide levels of 5 different perifusion columns from 3 independent differentiation trials. Panel D, mean ± s.e.m
glucagon levels of 4 different perifusion columns from 2 independent differentiation trials. E–F) Stage 7 cells were cultured in either
low glucose (8 mM, red) or high glucose (25 mM, blue) from days 20–33. E) At day 26, basal C-peptide secretion was measured in 2
independent differentiation trials after 24 h in culture media (mean ± s.e.m of 10–11 different wells per trial; * p b 0.05, t-test).
F) At day 33, intact monolayer cultures from low and high stage 7 glucose conditions were harvested for perifusion. Human C-peptide
secretion was measured in collected fractions (mean ± s.e.m of 4 different perifusion columns from 2 independent trials).
203Modeling human fetal pancreasglucose sensingmachinery required forβ-cell function. Glucose
is transported into β-cells by the glucose transporter
(predominantly GLUT1 in humans (De Vos et al., 1995;
Coppieters et al., 2011); Fig. 6B) and then phosphorylated by
glucokinase (GCK) prior to entering the glycolysis pathway
(MacDonald et al., 2005). We observed that GLUT1 transcript
levels were ~10-fold higher than in adult human islets, whereas
GCK levels were similar (Fig. 6A). However, immunofluorescent
staining revealed that GCK was co-expressed in insulin-positive
cell clusters (Fig. 6D), whereas GLUT1 proteinwas not (Fig. 6C).Notably, the same GLUT1 antibody displayed strong immu-
noreactivity in β-cells from adult human pancreas tissue
(Fig. 6B). Given the striking absence of GLUT1 protein in the
endocrine population, we next sought to determine if the
transcript was present in these cells. In situ hybridization
experiments revealed that GLUT1 mRNA was present in both
the polyhormonal endocrine cells and the surrounding non-
endocrine population (Fig. 6E). Therefore, it appears that
the glucose transporter in hESC-derived insulin/glucagon co-
positive cells may be transcribed, but not translated.
204 J.E. Bruin et al.ATP-sensitive potassium channels
Glucose metabolism elevates ATP levels in mature
β-cells, triggering closure of ATP-sensitive K+ (KATP) channels,
membrane depolarization, opening of voltage-sensitive Ca2+Figure 6 Characterization of glucose transport and sensing c
transporter 1 and glucokinase (GLUT1 and GCK) at day 33 relative t
line). B) GLUT1 is expressed in insulin-positive cells within adult hu
cells, but completely absent within the insulin/glucagon co-positive
was co-expressed in polyhormonal insulin/glucagon-positive cells
hybridization revealed that GLUT1 mRNA is expressed in pancreaticchannels and Ca2+-induced insulin secretion (MacDonald et al.,
2005). To assess KATP channel function, we performed a
non-radioactive rubidium (Rb+)-efflux assay (Li et al., 2013).
At d26, hESC-derived cells showed mild Rb+ efflux, but to aomponents in stage 7 cells. A) Gene expression of glucose
o levels in isolated adult human islets (indicated by dashed red
man pancreas. C) GLUT1 was highly expressed in hESC-derived
endocrine cells (scale bars = 50 μm). D) In contrast, glucokinase
within the bud structures (scale bars = 50 μm). E) In situ
endocrine cells within the bud structures (scale bars = 75 μm).
205Modeling human fetal pancreaslesser degree than βTC3 or MIN6 cells (Fig. 7A). Moreover,
unlike β-cell lines, Rb+ efflux in hESC-derived cells was not
inhibited by exposure to glucose or the sulfonylurea receptor
blocker, glibenclamide (Fig. 7A). A metabolic inhibitor
cocktail, which reduces cellular ATP levels and thus causes
opening of KATP channels, increased Rb+ efflux in cultured
β-cells but had no effect on Rb+ efflux in hESC-derived cells.
These data suggest that functional KATP channels were either
not expressed in hESC-derived cells or only present in a small
subset of cells.
KATP channels are composed of two subunits: the regulatory
sulfonylurea receptors (SUR1) and pore-forming KIR6.2
subunits. We examined the expression of KIR6.2 in hESC-
derived insulin-positive cells and detected little to no
immunoreactivity for KIR6.2 (Fig. 7B). We also examined the
formation of KATP channels using Western blot detection of
SUR1. Different stages of maturation and trafficking of SUR1
generate multiple molecular weight bands on SDS-PAGE gels.
In HL-1 cells, a cardiomyocyte derived cell line with significant
endogenous KATP activity, both the higher and lowermolecular
weight SUR1 bands were detected, consistent with formation
of functional,mature, KATP channels (Fig. 7C). However, in the
hESC-derived cells (d26–d33), only the lower molecular
weight band was observed. This finding is consistent with a
lack of functional KATP channels at the cell surface, in line with
our observation of little or no KATP-mediated Rb+ efflux.
Our gene array indicated that mRNA levels of KIR6.2 were
similar to that of adult human islets, but that ABCC8 (SUR1)
levels were significantly downregulated (Fig. 7D). Given that
these subunits should be expressed at a 1:1 ratio within
mature β-cells, we speculated that the observed discrepancy
in the subunit proportions (~5:1 KIR6.2:SUR1 transcript levels;
Fig. 7D) may also contribute to the defect in KATP channel
activity (Fig. 7A). Therefore, COSM6 cells were transfected
with varying ratios of KIR6.2:SUR1 plasmid (ensuring that the
total DNA transfectedwas the same in each condition) and Rb+
efflux was assessed. Our findings demonstrate that KATP
channel activity was detrimentally affected by a reduction in
the SUR1 subunit (Fig. 7E). In contrast, reducing the
KIR6.2 plasmid did not substantially impact Rb+ efflux, even
when a 10:1 ratio of SUR1:KIR6.2 plasmid was transfected
(Fig. 7E). These findings highlight that an appropriate
stoichiometric balance of Kir6.2 and SUR1 is required to
generate adequate KATP channel activity (Flagg et al., 2005),
and that stoichiometric mismatch may contribute to the
absence of functional KATP channels in hESC-derived cells.Discussion
In the present study, we characterize a differentiation
protocol that converts pluripotent hESCs into a mixed cell
population of immature pancreas cells, including budding
structures of NKX6.1-positive ductal cells adjacent to islet-like
endocrine clusters. These hESC-derived cells resembled a
mid-gestation human fetal pancreas and thus may be a useful
model for studying human pancreas development. Our studies
provide novel insights into several key elements of mature
β-cells that appear to be deficient in hESC-derived poly-
hormonal cells, such as GLUT1 protein expression, KATP
channel activity and prohormone processing enzymes. Until
hESC-derived insulin-secreting cells gain these features,glucose-stimulated insulin secretion will not be achieved
in vitro.
There are several lines of evidence to suggest that our in
vitro differentiation protocol provides a meaningful model
of human pancreas development. Firstly, our modified
protocol for inducing definitive endoderm formation, using
GDF8 and a GSK3β inhibitor, consistently proved to be more
efficient than the typical AA/WNT3A combination. Unlike
our other studies (Rezania et al., 2012; Bruin et al., 2013;
Rezania et al., 2013) this definitive endoderm protocol is
also serum-free, which is preferable for reproducibility.
Similar to previously published differentiation protocols
designed to produce insulin-secreting cells in vitro (Nostro
et al., 2011; D'Amour et al., 2006), we observed robust
induction of PDX1 in more than 90% of cells at d11 and then
NKX6.1 in over 70% of cells at d17. As with human fetal
pancreas (Riedel, 2011), the developing endocrine cells were
initially scattered and sparse, but increased in number over
time, as demonstrated by qPCR, immunofluorescent staining
of in situ cultures and paraffin sections, and hormone secretion
into the media. Moreover, the developing endocrine cells
transitioned into distinct islet-like clusters that resembled the
endocrine clusters in a mid gestation human pancreas (Riedel,
2011). For instance, the hESC-derived insulin-positive cells
co-expressed glucagon and NKX2.2, but were negative for
NKX6.1, which was instead expressed in neighbouring CK19-
positive/hormone-negative cells within the budding clusters.
Yet, unlike a mid-gestation human fetal pancreas, the rare
hESC-derived insulin-only cells lacked expression of NKX6.1
and PDX1. Approximately 6–10% of cells in our cultures
expressed insulin at d33 and INS gene levels were only 2-fold
less than whole adult pancreas, but comparable to levels in a
mid gestation human fetal pancreas (J Bruin and S Erener,
unpublished observations). These data suggest that our
differentiation protocol more accurately modeled whole
pancreas development rather than simply islet development.
We next examined whether our highly homogenous
PDX1-positive pancreatic progenitor cells differentiated into
both endocrine and exocrine lineages in vitro. Trypsin, an early
marker of developing acinar cells, was weakly expressed
throughout the cultures, including within the developing
pancreatic endocrine cells. This was unexpected since trypsin
and synaptophysin are not typically co-expressed during human
fetal pancreas development from 12w4d to 21w (A Asadi and J
Bruin, unpublished observations). Interestingly, PSTI was also
highly expressed in the insulin-positive cells, similar to human
fetal islets (Fukayama et al., 1986), suggesting that trypsin
activity was likely inhibited in the developing endocrine cells.
Given that trypsin-positive cells did not co-express other
exocrine markers, such as amylase or CPA1, and the cultures
showed no detectable trypsin activity (data not shown), we
concluded that these cells were unlikely to be comparable to
developing exocrine cells.
We next utilized our culturemodel of pancreas development
to study the phenotype of hESC-derived polyhormonal cells, as
the role of these cells in fetal pancreas remains controversial.
For instance, it is currently unclear why insulin/glucagon
co-expressing cells seem to be more “α-like” than “β-like”,
both in terms of their transcription factor profile (Riedel, 2011)
and their apparent preference to differentiate into α-cells
following transplantation (Rezania et al., 2011; Kelly et al.,
2011; Basford et al., 2012; Rezania et al., 2013). We first
Figure 7 Characterization of ATP-sensitive potassium channels in stage 7 cells. A) KATP channel activity was determined by
measuring rubidium (Rb+) efflux over time. hESC-derived cells were not responsive to either KATP channel inhibitors (glibenclamide
and glucose) or activators (metabolic inhibitors: oligomycin and 2-deoxy-D-glucose). In contrast, KATP channel activity in MIN6 β-cells
was appropriately stimulated by metabolic inhibitors and inhibited by the addition of glibenclamide; both glibenclamide and glucose
inhibited channel activity in another β-cell line, beta-TC3 cells. B) Immunofluorescent staining of KATP channel subunit Kir6.2 in stage
7 cells (scale bars = 100 μm). C) Total cell extracts from different stages of hESC cultures (d7-d33) and HL-1 cells were prepared and
proteins were analyzed by Western blot with an antibody against SUR1. D) Gene expression of KATP channel subunits, SUR1 and Kir6.2,
in hESC-derived cells at day 33, relative to levels in isolated adult human islets. E) SUR1 and Kir6.2 DNA was transfected into COS cells
to determine if the subunit ratio affected channel activity. Rb+ efflux in each condition was normalized to efflux in cells transfected
with a 1:1 ratio after 40 min.
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207Modeling human fetal pancreasexamined the hormone secretion kinetics of our hESC-derived
endocrine cells and established that although both insulin and
glucagon secretion increased throughout differentiation,
hormone secretion was not regulated by glucose, similar to
previous reports (D'Amour et al., 2006; Basford et al., 2012).
We also confirmed that our cells released both C-peptide and
glucagon in response to direct depolarization by both KCl and
arginine. We speculated that the absence of glucose-induced
insulin secretion could be due to the high glucose con-
centrations in our stages 3–7 media and thus, desensitization
of cells to glucose. Indeed, when cells were cultured during
stage 7 under lower glucose conditions, we observed increased
insulin secretion but no improvement in the sensitivity of
endocrine cells to glucose. Therefore, several markers of
mature β-cells were examined to identify possible defect(s)
in the glucose-stimulated insulin secretion pathway, including:
a) glucose transport and sensing mechanisms, b) KATP channels,
and c) proinsulin processing.
Our hESC-derived insulin-positive cells appear to be
similar to those produced by Nostro and colleagues (Nostro
et al., 2011). In a recent report, their cells were thoroughly
characterized by FACS-purifying the GFP/insulin-positive
cell population, which provided the advantage of a pure
population for analysis (Basford et al., 2012). In contrast,
our experiments were performed in whole, intact cultures,
thus preserving the endocrine cell microenvironment and
contact with neighbouring cells. Since transcript levels were
measured in mixed cultures, we also carefully assessed the
cellular localization of proteins and found key discrepancies
between gene and protein expression patterns. For instance, in
the mixed cultures at d33, GLUT1 mRNA levels were ~10-fold
higher than in human islets, but immunofluorescent staining
revealed that GLUT1 protein was virtually absent from the
insulin-positive cell population. Interestingly, Basford et al. did
not detect a difference in GLUT1 gene expression between
sorted GFP/insulin-positive and GFP/insulin-negative cells
(Basford et al., 2012), raising the possibility that GLUT1
expression may be discrepant at the protein level. Indeed, in
situ hybridization experiments revealed that GLUT1 transcript
was present in our hESC-derived endocrine cells, suggesting
that the glucose transporter was transcribed but not translated.
These data indicate that our hESC-derived insulin-secreting
cells may be lacking the mechanism to transport glucose into
the cell, the crucial first step for glucose-stimulated insulin
secretion.
Our studies also demonstrate that hESC-derived cells only
displayed mild K+ channel activity, which did not appear to be
mediated by functional KATP channels. HESC-derived cells
contained little immunoreactivity for KIR6.2. Although SUR1
could be detected in the hESC-derived cells (d26–d33), it was
not assembled with KIR6.2. Basford et al. demonstrated that
KATP channels were only active 45% of the time in isolated
hESC-derived insulin-positive cells, despite enriched gene
expression of the KATP channel subunits (Basford et al., 2012).
We also detected gene expression of KATP channel subunits in
our hESC-derived cell population, similar to that in human
islets, but noted that KIR6.2 transcript levels were ~5-times
higher than SUR1. Since these subunits should be expressed
in equal proportion within functional KATP channels, we
hypothesized that an inappropriate subunit ratio could affect
channel activity. Indeed, transfection experiments revealed
that Rb+ efflux was particularly sensitive to a reduction inSUR1 plasmid, whereas decreasing KIR6.2 had little effect on
channel activity. It remains to be determined whether the
ratio of SUR1:KIR6.2 is inappropriate at the single cell level.
Regardless, our findings illustrate that appropriate ratios of
KATP channel subunits are critical for its activity and this may
be a factor contributing to the lack of glucose-responsiveness
in hESC-derived insulin-producing cells.
Finally, we also demonstrate that there may be defects in
proinsulin processing in the hESC-derived polyhormonal cell
population. The formation of mature insulin hormone involves
translation of a single-chain proinsulin peptide, which is then
processed by prohormone convertases (PC1/3 and PC2) and
carboxypeptidase (CPE) into equimolar amounts of the mature
disulphide-linked insulin along with the cleaved connecting
peptide (C-peptide).Whilemost insulin-positive cells expressed
PC2, there was heterogeneous expression of PC1/3 in this
population, resulting in many insulin-positive/PC1/3-negative
cells that would presumably produce incompletely processed
proinsulin. Defective PC1/3 expression could be particularly
problematic, as lack of PC1/3 has been associated with more
severe defects in proinsulin processing than loss of PC2 in
transgenicmousemodels (Zhu et al., 2002; Furuta et al., 1998).
In summary these studies characterize a new differentiation
protocol that models human fetal pancreas development
in vitro. We demonstrated the utility of our hESC-derived cells
for understanding important characteristics of human fetal
pancreas cells that are difficult to study due to inaccessibility of
human fetal tissues. Our studies revealed several key features
of polyhormonal insulin-positive cells that differ from mature
pancreatic β-cells, including defects in glucose transporter
expression, KATP channel function and prohormone processing
enzymes. These deficiencies will require addressing with
further protocol modifications in order to achieve glucose-
stimulated secretion of mature insulin by hESC-derived
pancreatic endocrine cells in vitro.Acknowledgments
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